the injection site, resulted in improved retention of the marker in perilymph. Adhesive on the RW membrane effectively prevented leaks but also influenced fluid exchange between CSF and perilymph. We conclude that drugs can be delivered to the ear in a consistent, quantitative manner using intracochlear injections if care is taken to control the fluid leaks that result from cochlear perforation.
Introduction
Many therapies for the inner ear are being developed that require the application of drugs (sometimes in the form of nanoparticles), gene therapy agents or stem cells to the ear [Staecker and Rogers, 2013] . Although numerous drugs and viral vectors have been successfully applied intratympanically [Jero et al., 2001; Bowe and Jacob, 2010] , many substances do not readily penetrate into the perilymph at the round window (RW) membrane or at other sites. Perilymph levels of drugs and markers measured after intratympanic applications of a few hours' duration were highly variable even with well-controlled middle ear levels [Mynatt et al., 2006 . Perilymph drug levels appear to become less vari-able when drug is delivered for more prolonged periods [Wang et al., 2009] . However, concentration levels in the basal part of the scala tympani (ST) typically reach less than 3% of the applied concentration (summarized in Hahn et al. [2012] ). More consistent and efficient delivery would be expected when the solution was directly injected into the perilymph. With applications by intracochlear injection into the cochlear apex [Salt et al., 2006] or by injections through the RW membrane [Salt et al., 2007; Hahn et al., 2012] , concentrations in the perilymph were found to be higher, with lower variation and the substances were distributed more uniformly along the ST. Effective deliveries of viral vectors have been accomplished with single intracochlear injection procedures [Stöver et al., 1999; Kawamoto et al., 2001; Staecker et al., 2014] . Nevertheless, previous studies have suggested that the efficiency of delivery with injections though the RW membrane will be influenced by fluid leakage at the injection site [Salt et al., 2007] .
Injections through the RW in guinea pigs do not damage hearing [Kho et al., 2000] . However, a side effect of inner ear perforation in guinea pigs, mice and other rodents is the resulting efflux of fluid at the perforation site, driven by cerebrospinal fluid (CSF) entering at the base of the ST through the cochlear aqueduct. In guinea pigs the rate of efflux from a perforated cochlea is 0.5-1 μl/min [Moscovitch et al., 1973; Salt and Stopp, 1979; Ohyama et al., 1988] . Perilymph efflux from the perforated ear occurs at a similar rate in mice [Hirose et al., 2014] . If the volume flow displacing perilymph is not controlled, a substantial proportion of the injected solution will be displaced into the middle ear. In earlier studies, the RW niche was filled with hyaluronate gel before injections in an attempt to limit fluid efflux [Salt et al., 2007; Hahn et al., 2012] . The influence of fluid leakage on perilymph drug levels following injection is likely to be highly dependent on the delivery methods used. Many reports of drug delivery to the cochlea as single direct perilymphatic injections do not report their injection procedures in detail. Of those that have given details, injections into perilymph have been performed with hand-held 30-to 36-gauge needles [Stöver et al., 1999; Praetorius et al., 2007] or glass pipettes [Sellick et al., 2008] . In the present study, injections through the RW membrane were performed as rigorously as possible with an electronically controlled micropump, mounted on a micromanipulator and using sharp glass pipettes to minimize the size of the perforation and associated fluid leakage. Even with a high degree of care, the influence of fluid leaks remained. Procedures to control those leaks were therefore evaluated.
Materials and Methods

Animal Preparation
This study used 40 pigmented, NIH strain guinea pigs of both sexes weighing 400-600 g and bred in our own colony. Experimental protocols were in accordance with policies of the United States Department of Agriculture, the National Institutes of Health guidelines for the handling and use of laboratory animals, and were approved by the Animal Care Committee of Washington University under protocol No. 20100135 and 20130069. Animals were initially anesthetized with sodium thiobutabarbital (Inactin, Sigma, St. Louis, Mo., USA) 100 mg/kg and then maintained on isofluorane (0.8-1.2%) in oxygen using a tracheal cannula and mechanical ventilation, adjusted to maintain a 5% end-tidal CO 2 level measured with a CapnoTrue AMP (Bluepoint Medical, the Netherlands). A pulse oximeter (Surgivet, Waukesha, Wis., USA) was used to monitor heart rate and blood oxygen saturation, and a DC-powered thermistor-controlled heating blanket was used to maintain body temperature at 38 ° C. The head of the animal was held rigidly using ear and bite bars. The auditory bulla was exposed by a ventral approach and opened widely to expose the cochlea. The cochlear apex was first prepared for sequential perilymph sampling, as described in detail [Salt et al., 2006] . Marker solution containing sodium fluorescein or fluorescein isothiocyanate (FITC)-labeled dextran was injected into the perilymph through the RW membrane, either with or without procedures to limit fluid leakage at the injection site. After a delay of 40 min, ST perilymph was collected from the apex using a sequential sampling technique. Only one injection and sampling procedure were performed in each animal.
Solutions
The injected solution consisted of artificial perilymph containing (in m M ): NaCl 125, KCl 3.5, NaHCO 3 25, CaCl 2 1.3, MgCl 2 1.2, NaH 2 PO 4 0.75 and dextrose 5, to which fluorescent marker was added. Initial experiments used 20 m M sodium fluorescein but the high sensitivity of measurement assays allowed the use of 1 m M sodium fluorescein for most of the experiments. In 8 experiments FITC-labeled dextran (FD4, Sigma; FW 3,000-5,000) was used as the marker, added to artificial perilymph at a concentration of 2.5 m M .
Injections into the ST Solutions were injected through the RW membrane either manually (n = 6) or with a digitally controlled pump (n = 34). For manual injections a 10-μl Hamilton gas-tight syringe fitted with a 30-gauge stainless-steel hypodermic needle (320 μm outer diameter) was either hand-held or held in a manipulator. The tip of the needle was bent at a 90-degree angle approximately 2 mm from the tip to allow it to enter the ST from the RW niche. A 5-μl volume of fluorescein solution was injected over a 20-second period. This was the method described by Stöver et al. [1999] .
For pumped injections, a 100-μl gas-tight syringe (1710TLL Hamilton) was mounted on the pump (Ultrapump, World Precision Instruments, Sarasota, Fla., USA) which was held in a micromanipulator. The syringe was coupled to a 1-mm diameter glass injection pipette with a Plexiglass coupler (MPH6S10, World Precision Instruments). The glass injection pipette was pulled in an electrode puller and then beveled at a 60-degree angle (Narishige EG-40 beveler), to a tip diameter of 10-25 μm. Due to the taper of the pipette, RW perforation was estimated to be 20-40 μm in diameter, depending on the insertion depth. Injections were performed at a rate of 0.4 μl/min for 7.5 min, injecting a total of 3 μl into the ST, which is approximately half the volume of the guinea pig ST [Thorne et al., 1999] .
In addition to pumped injections with no attention to sealing ('no remedy', n = 5), a number of different methods were used to control fluid leakages at the injection site, as shown schematically in figure 1 . One of two gels, 1% sodium hyaluronate (Healon ® , Abbott Medical Optics, Santa Ana, Calif., USA, n = 3) or 17% poloxamer 407 (Spectrum Chemicals, Gardena, Calif., USA, n = 3) were used as 'internal sealing' agents when used as the background medium for the injection solution. 'External sealing' was provided by a medical grade biologically compatible cyanoacrylate adhesive, Tissumend ® (Veterinary Products Laboratories, Phoenix, Ariz., USA, n = 4) which is approved for use in animals. Either before or after the injection through the RW membrane, fluid was wicked away and ∼ 1 μl of adhesive was applied to fill the bony annulus of the RW. In 4 additional experiments, Healon and Tissumend were combined.
In 15 experiments, an identical injection protocol was used with the delivery pipette inserted into the ST through a fenestration of the bony wall. The injection pipette was sealed into the bone with cyanoacrylate and silicone adhesives [Salt et al., 2006] . This method prevented all fluid leakage at the injection site.
Sequential Sampling of Perilymph from the Cochlear Apex
Before injection, the cochlear apex was prepared for perilymph sampling as detailed elsewhere [Mynatt et al., 2006] . The mucosa was removed, and the bone was allowed to dry. A layer of thin cyanoacrylate (Permabond 101, Permabond LLC, Pottstown, Pa., USA) was applied followed by layers of two-part silicone adhesive (Kwik-Cast, World Precision Instruments, Sarasota, Fla., USA). The silicone was applied thinly on the apical bone but multiple layers were built up at the edges to form a hydrophobic cup. At the time of sampling, a 30-degree House stapes pick (N1705 80, Bausch and Lomb Inc.) was used to perforate the adhesives and bone at the apex. The emerging fluid accumulated in the silicone cup, isolated from the mucosa of the bulla. Fluid was collected in hand-held, blunt-tipped capillary tubes (VWR 53432-706) marked for a nominal 1-μl volume. Each 1-μl sample took 40-60 s to collect. The volume of each sample was determined by length measurement under a calibrated dissecting microscope. Ten samples were collected, and each was analyzed separately. As the ST perilymph volume is approximately 5 μl in the guinea pig, the total fluid volume collected (10 μl) substantially exceeded the ST volume, with later samples containing CSF that had passed through the ST [Mynatt et al., 2006] .
Sample Handling and Analysis
Perilymph samples and 3 samples of the injected solution were each diluted in 150 μl of artificial perilymph. Reference standards were made by performing 5 serial 10× dilutions of the injected solution in artificial perilymph. Diluted fluid samples and equal volumes of standards were transferred to a 96-well plate and read in a Synergy HT plate reader (Bio Tek, Winooski, Vt., USA). The Solver capability of Microsoft Excel was used to fit a sigmoid (Hill) function to the fluorescence versus concentration data from the standards and subsequently used to convert brightness readings to concentration. Perilymph concentrations were calculated using individual sample and dilutant volumes. Sample concentration data were normalized with respect to the injection concentration of the experiment.
One useful metric was to calculate how much of the injected marker was recovered in all of the samples collected in each experiment. The amount of marker (concentration × volume) was summed across the 10 samples and expressed as a percentage of the total marker injected. Fluid leakage to the middle ear at the RW membrane perforation results in marker loss. Loss also occurs by other processes, some driven into CSF during the injection, some diffusing into adjacent fluid and tissue compartments, and some lost by elimination to blood.
Statistical differences between experimental groups were established by one-way ANOVA using Sigmaplot v13 (Systat Software Inc., San Jose, Calif., USA). 
Results
Injections through the RW Membrane
The fluorescein concentrations of samples taken from the apex following fluorescein injections through the RW membrane are summarized for 4 of the experimental conditions in figure 2 . For manual injections with a 30-gauge needle, measured perilymph fluorescein levels were extremely low. For hand-held injections, the mean highest sample concentration was 0.92% of the injected concentration (SD 0.28, n = 3). Very similar results were found with manipulator-held injections from the 30-gauge needle (mean 0.84%, SD 0.31, n = 3). These data were not significantly different for hand-held and manipulator-held conditions so the data were pooled in the figure. With injections from the much smaller glass pipette, perilymph fluorescein levels were substantially higher than with the 30-gauge needle, even when there was no control of fluid leakage ('glass pipette: no remedy' condition). The average highest concentration reached 6.1% of the injected concentration (SD 2.41, n = 5). The low initial sample (representing perilymph orig- Higher sample concentrations occur when less fluorescein is lost by fluid leaks. a Samples taken after injection through a 30-gauge hypodermic needle ('30-gauge needle: no remedy'; n = 6) contained extremely low fluorescein levels. b Injections through a 10-to 25-μm glass pipette ('glass pipette: no remedy'; n = 5) showed higher fluorescein content, with the highest concentration in samples 3 or 4, corresponding to those originating from the basal region of the ST. c When fluorescein was injected in a Healon gel matrix ('glass pipette: Healon'; n = 3), sample concentrations in some experiments were higher than with 'no remedy'. d When Tissumend was applied to the RW membrane ('glass pipette: Tissumend', n = 4) either after pipette insertion but before injection (solid lines) or after injection and pipette withdrawal (dashed lines), sample curves were even higher.
inating in apical regions) and highest concentration in samples 3 or 4 (representing perilymph originating in the basal turn of the ST) confirm the basal-apical concentration gradient that results from the injection of marker into the basal turn of the ST through the RW membrane. When fluorescein was injected in a background of Healon gel, higher concentrations were found in the samples, with a mean peak concentration of 12.4% of the injected concentration (SD 3.1, n = 3) in sample 3. Similarly, when the injection location in the RW membrane was sealed with Tissumend, sample concentrations were higher with the peak concentration averaging 19.1% of the injected concentration (SD 5.5, n = 4). ANOVA testing (all pairwise, Student-Newman-Keuls) based on the peak sample concentrations of the measured curves showed all four groups to be significantly different from each other (30 G vs. glass pipette: no remedy, p = 0.014; Tissumend vs. no remedy, p < 0.001; Tissumend vs. Healon, p = 0.013; Healon vs. no remedy, p = 0.015).
A measure of retention of fluorescein in perilymph was calculated by summing the solute from all 10 samples collected in each experiment and expressing it relative to the total amount injected. The degree of fluorescein retention for the different experimental procedures is summarized in figure 3 . Recovery of fluorescein was extremely low following injection from a syringe with a 30-gauge needle. This procedure generated a perforation of the RW membrane that was clearly visible with the operating microscope and was associated with rapid accumulation of fluid in the RW niche. In contrast, perforations made with the glass injection pipette were not visible with the operating microscope and were only apparent by fluid accumulation on the RW membrane. The difference in fluorescein recovery between injections with a 30-gauge needle (mean 0.92%, n = 6) and injections made with a glass microelectrode (mean 10.3%, n = 5) were highly significant (two-tailed t test, p < 0.001).
Our results show that gels used as the injection matrix for 'internal sealing' or adhesive applied to the RW membrane for 'external sealing' both improved the amount of fluorescein recovered in the samples. This finding is consistent with all the treatments reducing loss to the middle ear from fluid leakage. The treatment providing best retention of fluorescein in perilymph was the Tissumend adhesive, which allowed 34.3% of the injected fluorescein to be recovered. The combination of external and internal sealing with Tissumend and Healon did not surpass the effect of Tissumend alone. ANOVA testing (multiple comparisons vs. the no remedy group, Holm-Sidak) showed that poloxamer (p = 0.044), Healon (p = 0.026), Tissumend (p = 0.002) and Healon + Tissumend (p = 0.011) all elevated marker recovery significantly.
Injections through a Fenestration in the Bony Wall of the ST
With injections through the RW membrane, it was uncertain whether a fluid-tight seal was being achieved by any procedure. We therefore compared perilymph sample concentrations for injections from pipettes sealed into a fenestration of the bony wall of the ST, where the absence of fluid leaks could be assured. This experiment was originally intended as a control, to demonstrate that without marker loss through the RW membrane, perilymph concentration would not be influenced by Tissumend on the membrane. Figure 4 shows the measured amounts of marker recovered following fluorescein or FITC-dextran injections when the RW membrane was not manipulated in any way (no remedy) and when it had been coated with Tissumend. Contrary to our expectations, the retention of marker in perilymph was significantly higher for both markers when Tissumend coated the RW membrane (fluorescein t test, p < 0.001; FITC-dextran t test, p = 0.0047). FITC-dextran is a much larger molecule (FW ∼ 4,000) than fluorescein and would not be expected to readily permeate the RW membrane. The higher amount of dextran recovered compared to fluorescein in both conditions is accounted for by lower losses for dextran by other elimination processes, such as blood. In the dextran studies it was noted that in the no remedy condition the RW remained clear of fluid so that no dextran loss could have occurred through the membrane. Nevertheless, Tissumend on the RW membrane significantly increased dextran retention, averaging 60.0%. Tissumend was therefore elevating the concentration of fluorescein and dextran in perilymph by a mechanism that did not involve marker efflux through the RW membrane in the untreated state.
Discussion
The retention of drug in the ear following intracochlear injection is demonstrated to be strongly dependent on the application protocol, primarily the size of the perforation made in the RW membrane. Injection from a 30-gauge needle resulted in low marker retention, with less than 1% of the marker recovered in samples taken 40 min after injection. This shows that injections from 30-gauge needles are a very inefficient way to deliver a drug or other substance to the ear. Although some applications of this type may have achieved the intended purpose [Stöver et al., 1999] , a delivery protocol with higher efficiency would generally be preferable. Delivery through a micropipette provides a dramatically better retention, reaching over 10% in this study. The use of gel or adhesive to minimize fluid leakage for injections through the RW membrane is shown to further increase the marker levels retained in perilymph. The amount of drug or marker was typically more than doubled when fluid leakage at the injection site was controlled with gel or glue. The degree of control by such procedures is undoubtedly influenced by the primary delivery method and similar sealing procedures may not be as effective for injections that make substantially larger perforations of the RW membrane. Nevertheless, the present study shows that higher perilymph concentrations can be achieved by intracochlear injections when fluid leakage at the injection site is controlled. With fluid leakage present, the amount required to displace drug solution from the ST is extremely small and may not be visible with an operating microscope. This potentially gives a false impression that no leakage is occurring so the problem may be overlooked. Fluorescent markers provide a readily available tool to assess perilymph composition quantitatively, allowing the influence of leaks to be quantified.
The influence of Tissumend adhesive on the RW membrane appears to be more complex than just preventing fluid leaks from the perforation site in the RW membrane caused by pipette insertion. When markers were applied by injections through the bony wall of the ST, where the RW membrane was untouched, significantly higher levels of both fluorescein and FITC-dextran were found after the RW membrane had been occluded with Tissumend even though there was no possible volume leak at the RW membrane in this condition. Our explanation for this phenomenon is that Tissumend application not only stops leaks, but also makes the RW membrane rigid, decreasing its compliance and mechanically affecting fluid physiology. RW compliance of the guinea pig has been estimated to be 0.14 nl/Pa [Dé-cory et al., 1990; Wit et al., 2003] . Considering that respiratory pressure fluctuations in perilymph are 0.3-1.0 mm Hg (40-133 Pa) [Takeuchi et al., 1991; Böhmer, 1993] , each respiratory cycle is calculated to result in a volume displacement across the cochlear aqueduct of 5.6-18.6 nl. We incorporated a CSF-perilymph exchange of variable volume into our inner ear fluids simulation program (version 3.083, available for download from our website at http://oto.wustl.edu/cochlea/). A reciprocating volume exchange between perilymph and CSF of just 3 nl per respiratory cycle (3 nl/s) was sufficient to account for the lower marker levels in the 'no remedy' condition and for an increased level of marker when Tissumend was applied (assuming Tissumend abolishes the exchange). It should be emphasized that Tissumend application does not occlude the cochlear aqueduct. The rate at which samples were collected from the apex during sequential perilymph sampling from Tissumend-treated ears was similar to untreated animals. Our data are therefore consistent with an ongoing CSF-perilymph exchange contributing to perilymph status at the base of the ST, and to the perilymph concentrations of drugs applied to the normal guinea pig. For injections of drugs and markers through the RW membrane, we conclude that the improved retention achieved with Tissumend likely results from the control of fluid leakage at the injection site and a decreased loss to the CSF compartment from pressure-driven reciprocating fluid oscillation. Further studies are necessary to characterize the kinetics of CSF-perilymph communications in more detail. Fluid leaks during injection and exchange of fluid between the ST and CSF may not occur to the same degree in humans as seen here in guinea pigs. Although the human cochlear aqueduct is thought to be functionally patent in younger humans, it may close in some older adults [Marchbanks and Reid, 1990; Wagner and Walsted, 2000] . A morphologic study found the minimum diameter aqueduct to average 138 μm in humans, and to be filled with fluid or loose connective tissue in 93% of 101 specimens [Gopen et al., 1997] . Category of patency did not correlate with age in this study. In addition, while intracranial pressure may be positive (7-15 mm Hg) while supine in normal adults, it becomes negative when upright [Andresen et al., 2015] . Future intracochlear drug and cell-based therapies will have to deal with the variations in communication across the cochlear aqueduct across the spectrum of patients that will undoubtedly include children.
It has recently been suggested that microperforations of the RW membrane may allow intratympanically applied drugs to transiently penetrate into the perilymph while limiting volume efflux of the type we have studied here [Kelso et al., 2014] . In vitro measurements made in that study confirmed that perforations made with a 12.5-μm probe (of comparable size to the injection pipettes used in this study) increased diffusion of drug across the membrane. It remains to be demonstrated whether a similar increase in drug entry occurs in vivo, when efflux of perilymph will occur through the perforation as shown by our data. Nevertheless, the possibility that microperforations could allow drugs to be delivered to the perilymph more effectively without the need for intracochlear injections is an exciting possibility.
Future studies also need to investigate how marker retention over longer time periods is influenced by manipulations to suppress fluid leaks. Whether and how fast the perforation heals and whether effective longterm closure is obtained by the procedures that reduce leaks in the short term must be evaluated. In addition, possible long-lasting effects of sealing procedures on cochlear function and on RW membrane status must be studied. Cai et al. [2013] have shown that RW occlusion with 1 μl of Vetbond (a very similar procedure to that used here) had only minor influence on auditory brainstem (13.5 dB elevation) and distortion product otoacoustic emission responses measured 8 weeks after the procedure in rats.
The ultimate goal of this work is to devise procedures facilitating drug, gene or cell-based therapies of the inner ear through intracochlear and intralabyrinthine applications to the perilymph of humans. Such techniques need to preserve auditory function (i.e. to be safe for hearing) and to be quantitatively consistent in pharmacokinetic terms.
Conclusions
Drugs injected directly into the perilymph of the inner ear are rapidly displaced by fluid efflux at the injection site, resulting in inefficient and variable delivery. Fluid efflux can be controlled by 'internal sealing' procedures, such as by applying the drug in a gel, or by an 'external sealing' procedure, using adhesive. More efficient and consistent delivery is possible when fluid leakage at the injection site is controlled.
